Cargando…
Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction
Cardiovascular disease is the leading cause of death worldwide. Within the treatment armamentarium, beta-blockers have demonstrated efficacy across the spectrum of cardiovascular disease – from modification of a risk factor (ie, hypertension) to treatment after an acute event (ie, myocardial infarct...
Autores principales: | Frishman, William H, Henderson, Linda S, Lukas, Mary Ann |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663448/ https://www.ncbi.nlm.nih.gov/pubmed/19337551 |
Ejemplares similares
-
Carvedilol in hypertension treatment
por: Stafylas, Panagiotis C, et al.
Publicado: (2008) -
Carvedilol for Treatment of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
por: Thenappan, Thenappan, et al.
Publicado: (2021) -
Carvedilol Prevents Ovariectomy-Induced Myocardial Contractile Dysfunction in Female Rat
por: Ribeiro, Rogerio Faustino, et al.
Publicado: (2013) -
Use of carvedilol in hypertension: an update
por: Leonetti, Gastone, et al.
Publicado: (2012) -
Carvedilol in the Treatment of Portal Hypertension
por: Al-Ghamdi, Hamdan
Publicado: (2011)